HSV-1/2 gD Antibody (2C10): sc-56988

HSV-1/2 gD Antibody (2C10) is a mouse monoclonal IgG2a antibody that detects glycoprotein D (gD) of Herpes Simplex Virus 1 and 2 by western blotting (WB) and immunofluorescence (IF). Anti-HSV-1/2 gD antibody (2C10) plays a critical role in understanding the mechanisms of viral entry and pathogenesis, as glycoprotein D is essential for the fusion of the viral envelope with the host cell membrane. HSV-1/2 gD (2C10) antibody recognizes a protein located on the surface of the virus that is pivotal for establishing a stable connection with cellular receptors, which is a prerequisite for viral entry. The interaction of gD with its receptors on the host cell initiates a series of conformational changes that facilitate the fusion process, allowing the viral genome to enter the host cell. The presence of gD on the viral surface and its ability to bind to specific receptors underscores its significance in the infectivity of both HSV-1 and HSV-2, making gD a valuable target for therapeutic interventions and vaccine development. HSV-1/2 gD monoclonal antibody (2C10) serves as an essential tool for researchers studying the dynamics of herpes simplex virus infections and the role of glycoproteins in viral pathogenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-1/2 gD Antibody (2C10) References:

1. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.  |  Bernstein, DI., et al. 2005. Clin Infect Dis. 40: 1271-81. PMID: 15825029
2. Glycoprotein D adjuvant herpes simplex virus vaccine.  |  Bernstein, D. 2005. Expert Rev Vaccines. 4: 615-27. PMID: 16221064
3. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.  |  Awasthi, S., et al. 2014. Expert Rev Vaccines. 13: 1475-88. PMID: 25138572
4. Herpes simplex virus glycoprotein D relocates nectin-1 from intercellular contacts.  |  Bhargava, AK., et al. 2016. Virology. 499: 267-277. PMID: 27723487
5. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.  |  Yan, Y., et al. 2021. mSphere. 6: PMID: 33910988
6. Herpes Simplex Virus Type 2 Glycoprotein D Inhibits NF-κB Activation by Interacting with p65.  |  Li, C., et al. 2021. J Immunol. 206: 2852-2861. PMID: 34049972
7. Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.  |  Mahant, AM., et al. 2022. J Infect Dis. 226: 1489-1498. PMID: 35834278
8. Greater Durability and Protection against Herpes Simplex Viral Disease following Immunization of Mice with Single-Cycle ΔgD-2 Compared to an Adjuvanted Glycoprotein D Protein Vaccine.  |  Mahant, AM., et al. 2023. Vaccines (Basel). 11: PMID: 37631930
9. Development of recombinant rotavirus carrying herpes simplex virus 2 glycoprotein D gene based on reverse genetics technology.  |  Kawamura, Y., et al. 2024. Microbiol Immunol. 68: 56-64. PMID: 38098134
10. Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D.  |  Slein, MD., et al. 2024. Cell Rep Med. 5: 101417. PMID: 38350452

The preferred HSV-1 gD antibody is HSV-1 gD Antibody (DL6): sc-21719.